Biomerica Inc (Biomerica) in a biomedical technology company that undertakes the development, manufacturing and marketing of medical diagnostic products based on immunoassay technology. These products are used to detect and monitor chronic diseases such as diabetes, gastrointestinal diseases, certain esoteric tests, and food intolerance. The company reports its operations under single segment, the design, development, marketing and sales of diagnostic kits. Biomerica serves two markets: point of care (physicians' offices and over-the-counter drugstores); and clinical laboratories.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Biomerica is conducting research to develop COVID-19 diagnostic tests and to obtain regulatory approval of two tests for the gastrointestinal market. In FY2022, the company spent US$1.6 million and has eight employees working towards its R&D activities. The company's unique diagnostic guided therapy (DGT) enables physicians to identify patient-specific foods. DGT focuses on whether removal of pork, milk, onions, sugar, or chickpeas alleviate or enhance an individual's symptoms of IBS. Biomerica also conducted research to develop patented diagnostic guided therapy products for treatment of inflammatory diseases and gastrointestinal diseases such as irritable bowel syndrome (IBS). Its product In Foods IBS is designed for both point-of-care testing and clinical labs. It also conducting clinical trials for investigating the performance of its proprietary H. pylori test, designed to enhance the specificity and sensitivity of H. pylori testing and improve monitoring of treatment which can lead to ulcers and possibly stomach cancers. Biomerica is conducting these clinical studies at the University of Southern California (USC), and a European University.